Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US team finds Parkinson's risk factor

This article was originally published in Clinica

Executive Summary

In what could pave the way to a screening test for Parkinson's disease, US researchers have identified a biomarker for the disorder. The researchers found that high levels of MAO-B, an enzyme that regulates nerve activity in the brain, cause Parkinsonian symptoms in mice. The research could lead to earlier diagnosis and hence treatment of the condition, which could help slow disease progression, claimed the researchers, based at the Buck Institute for Age Research, in Novato, California. The findings are published in the February 20 issue of online Journal PLoS One.

You may also be interested in...



Coronavirus Pipeline: GSK And Clover Add To Collaborations

Companies continue to throw their hats into the ring against the virus, with strategies ranging from ‘off the shelf’ molecules to novel vaccine and anti-viral therapies

Switzerland And UK Work On Closer Medtech Ties As EU Links Fall Apart

Switzerland’s current economic and trading relationship with the UK is based on its MRA with the EU. So, where does this leave the two countries in trading with one another now each of their relationships with the EU are under threat?

AstraZeneca Looks To FluMist Experience In COVID-19 Efforts

The UK firm speaks about its efforts to tackle the virus as a recent spike in COVID-19 cases outside China heighten concerns.

Topics

UsernamePublicRestriction

Register

MT046199

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel